Drug Profile


Alternative Names: PF 6252616; PF-06252616

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Kennedy Krieger Institute; Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy
  • Phase I/II Limb girdle muscular dystrophies

Most Recent Events

  • 01 Oct 2016 Pfizer initiates enrolment in a phase II extension trial for Duchenne muscular dystrophy (In children, In adolescents) in USA (NCT02907619)
  • 14 Sep 2016 Pfizer plans a phase II extension trial for Duchenne muscular dystrophy (In children, In adolescents) in USA, United Kingdom, Canada and Japan (NCT02907619)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top